Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing…
2017/05/23 – Quantum Genomics to Host Key Opinion Leader Event Focused on Phase IIa Hypertension Data and the Upcoming Clinical Trial in the United States
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/05/09 – Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/04/25 – Quantum Genomics appoints Bruno Besse as Chief Medical Officer
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/03/30 – 2016 annual financial results and next development steps in 2017
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/03/14 – Quantum Genomics announces positive data from new preclinical studies with QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/02/20 – 2017 financial calendar – Quantum Genomics has joined the Pass French Tech program
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/02/02 – Quantum Genomics granted key European patent for QGC011 combination therapy program
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…